ORKA
Oruka Therapeutics, Inc.- Healthcare
- Biotechnology
- $5.57B market cap
Forecast run · Sep 14, 2026Upside rank 648 of 3,136
Model Signal
ForecastQ Daily Probabilities
52.3%
35.7%
33.8%
Analyst Consensus
Recommendation2.00/5 Buy
Last price$92.38
Price target$149.56
Implied move+61.9%
Analysts9
ForecastQ Portfolios
Company Profile
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.